Heartflow, Inc. develops AI-enabled software for non-invasive detection and management of coronary artery disease. Its updates center on the Heartflow Platform and related analyses, including Heartflow FFRCT Analysis, Heartflow Plaque Analysis and Heartflow Roadmap Analysis, which use coronary CT imaging and software-based interpretation to support cardiovascular care.
Recurring news includes quarterly results, account adoption, payer coverage and reimbursement for Plaque Analysis, clinical evidence presented at cardiology meetings, patient registries such as GAMEFILM and NAVIGATE-PCI, investor conference activity, intellectual property enforcement and additions to Heartflow’s product platform such as PCI Navigator.
Heartflow (Nasdaq: HTFL) will report Q1 2026 financial results after market close on May 14, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live and archived webcast available on the company's Investor Relations website for 12 months.
Participants must register online to receive dial-in numbers and a unique PIN and are encouraged to register at least 15 minutes before the call.
Summary not available.
Heartflow (Nasdaq: HTFL) reported fourth-quarter and full-year 2025 results: Q4 revenue $49.1M (+40% YoY) and FY2025 revenue $176.0M (+40% YoY). Gross margin expanded to 79.5% in Q4 and 76.8% for the year. Cash, cash equivalents and investments totaled $280.2M.
Management issued 2026 revenue guidance of $218M–$222M (~24%–26% growth) and projected a non-GAAP gross margin of 80%–81%. Installed base and Plaque coverage gains cited as commercial catalysts.
Heartflow (Nasdaq: HTFL) announced new clinical evidence and launched the NAVIGATE-PCI registry to advance AI-guided CAD care. Key findings include a cohort of >15,000 patients with up to 16 years follow-up showing extensive plaque volume confers a 4x higher MACE risk, DECIDE data on ~3,800 patients improving lipid outcomes, and a US payer budget analysis projecting $140 million population savings and cost-effectiveness within two years. The NAVIGATE-PCI Registry has enrolled its first patient toward a planned 5,000-patient evaluation of CT-guided PCI planning.
Heartflow (Nasdaq: HTFL) announced management will participate in a fireside chat at the Morgan Stanley Technology, Media & Telecom Conference in San Francisco on March 3, 2026.
The presentation is scheduled for 10:45 a.m. PT / 1:45 p.m. ET, with a live webcast and archived replay available via the company's Investor Relations website.
Heartflow (Nasdaq: HTFL) will report fourth quarter and full year 2025 financial results after market close on March 18, 2026. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day with a live webcast and archived replay available for 12 months.
Investors must register to receive dial-in numbers and a unique PIN; participants are encouraged to register at least 15 minutes before the call.
Heartflow (Nasdaq: HTFL) announced expansion of its GAMEFILM Registry on February 12, 2026 to include former NBA and NHL players, building on an initial phase with NFL alumni.
The non-invasive registry uses AI-powered Heartflow Plaque Analysis with CCTA across 15 U.S. sites, has enrolled over 140 retired athletes and aims for up to 300 participants to study coronary plaque and risk.
Heartflow (Nasdaq: HTFL) announced that Aetna now covers Heartflow Plaque Analysis across Commercial, Medicare Advantage, and Aetna Better Health Medicaid plans, effective December 23, 2025 for patients with acute or stable chest pain and 1–69% coronary stenosis on coronary CTA. This makes Aetna the fourth major national payer to align coverage with EviCore and expands access to the majority of insured lives in the U.S.
Reimbursement moved forward with new Category I CPT code 75577 effective January 1, 2026, establishing 0.85 RVUs for physicians and a combined total of 4.00 RVUs. The release cites real-world evidence including the DECIDE Registry (>50% management change) and FDA clearance with 95% agreement to IVUS.
Heartflow (Nasdaq: HTFL) said company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 1:30 p.m. PT / 4:30 p.m. ET. A live webcast and archived replay will be available on Heartflow's Investor Relations website at https://ir.heartflow.com.
The presentation will cover recent company developments and outlook for investors; timing and access details are provided for shareholders and analysts.
Heartflow (Nasdaq: HTFL) announced that the American College of Cardiology and American Heart Association published scientific statements endorsing the prognostic value of quantitative coronary plaque assessment and highlighting the coronary CTA + Heartflow pathway for personalized CAD management on Dec 18, 2025.
Heartflow said its Plaque Analysis is the only FDA-cleared, AI-powered plaque quantification tool with 95% agreement to IVUS using blinded core-lab adjudication. The company cited real-world evidence including the DECIDE registry, where Plaque Analysis changed medical management in more than 50% of patients, and a FISH&CHIPS cohort validation presented at AHA 2025.